Skip to main content

Provider

By Dave Muoio | 01:29 pm | November 18, 2020
Lucira's molecular testing kit allows individuals to collect their own nasal sample and insert it into a device that provides results in under 30 minutes. The company is aiming to sell the single-use tests for roughly $50.
By Mallory Hackett | 01:00 pm | November 18, 2020
The earbud come equipped with artificial intelligence to isolate unwanted noises and enhance music, conversations, TV and other sounds.
By Sara Mageit | 12:25 pm | November 18, 2020
A reduction of 134 admission days was recorded in a group of 33 patients. 
By HIMSS TV | 09:43 am | November 18, 2020
Othman Abahussein, CEO of Nala, discusses how government initiatives are helping to meet user demands and drive digital health in the Kingdom of Saudi Arabia, reflected in the rise of telemedicine and e-prescriptions.
By HIMSS TV | 06:00 pm | November 17, 2020
Katya Hancock, Investor Network director at StartUp Health, says although Q3 2020 was the largest quarter for digital health funding in history, there's still a lot of work to do to address the most pressing healthcare needs.
By Laura Lovett | 04:09 pm | November 17, 2020
This morning at WISH 2020 Tom Insel and other panelists discussed the opportunities for applying tech to the global mental health shortage. 
By Mallory Hackett | 12:18 pm | November 17, 2020
 The cognitive behavioral therapy for insomnia program is designed to be an end-to-end virtual experience. 
By Dave Muoio | 11:30 am | November 17, 2020
Backed by an unannounced $3.2 million seed funding round from 2019, the virtual mental healthcare startup has announced three new partner schools and the official launch of its integrated "Managed Care Program" offering.
By HIMSS TV | 08:28 am | November 17, 2020
Dr. Osama Elhassan, coordinator of the ZIMAM initiative, says digital skills should be prioritized by the workforce to help improve workflows and care pathways.
By Sara Mageit | 06:10 am | November 17, 2020
Seventy-seven per cent of mobile phishing attempts on pharmaceutical organisations through the third quarter of 2020 intended on delivering malware.